What should I monitor while on semaglutide if I have heart disease?

Six monitoring parameters I recommend for men with established CVD on semaglutide: blood pressure every two weeks during dose escalation (the drug produces modest BP reduction, men on multiple antihypertensives may need dose adjustment as pressure improves); resting heart rate trend using any wearable device (watch for sustained increases above 8–10 bpm over pre-treatment baseline); hs-CRP at six months (the inflammatory reduction from visceral fat loss is a primary mechanism of cardiac benefit, documenting it is clinically useful); HbA1c if you were pre-diabetic at baseline (normalization may prompt review of any glucose-lowering medications); ApoB at six months (semaglutide modestly reduces triglycerides and VLDL, which may improve ApoB alongside LDL); and any new upper abdominal symptoms that could indicate cholecystitis, a documented side effect of rapid weight loss and GLP-1 therapy.

Persistent resting heart rate elevation above 10 bpm over baseline, blood pressure dropping below 100/60 mmHg on home monitoring, new palpitations, or any cardiac symptoms during treatment warrant a direct call to your cardiologist rather than waiting for a scheduled visit. The SELECT trial monitored these parameters systematically; home monitoring replicates that vigilance in a practical context. (Lincoff et al., NEJM, 2023)

Cardiologist's calibrated position, Solid (1) for this monitoring framework. These parameters were tracked in the SELECT trial and are clinically specific.

What to do: At initiation, establish baseline measurements for all six parameters. Schedule a three-month check-in, sooner if blood pressure or heart rate responses are significant.

For the full picture, read The Drug That Surprised Cardiologists.